| (19) |
 |
|
(11) |
EP 3 572 093 A8 |
| (12) |
CORRECTED EUROPEAN PATENT APPLICATION |
|
Note: Bibliography reflects the latest situation |
| (15) |
Correction information: |
|
Corrected version no 1 (W1 A1) |
| (48) |
Corrigendum issued on: |
|
15.01.2020 Bulletin 2020/03 |
| (43) |
Date of publication: |
|
27.11.2019 Bulletin 2019/48 |
| (22) |
Date of filing: 31.03.2015 |
|
| (51) |
International Patent Classification (IPC):
|
|
| (84) |
Designated Contracting States: |
|
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL
NO PL PT RO RS SE SI SK SM TR |
|
Designated Extension States: |
|
BA ME |
|
Designated Validation States: |
|
MA |
| (30) |
Priority: |
31.03.2014 WO PCT/IB2014/000467
06.03.2015 WO PCT/IB2015/000288
|
| (62) |
Application number of the earlier application in accordance with Art. 76 EPC: |
|
15722580.6 / 3125936 |
| (71) |
Applicant: Debiopharm International SA |
|
1002 Lausanne (CH) |
|
| (72) |
Inventors: |
|
- TANAKA, Hiroaki
1004 Lausanne (CH)
- MOULON, Corinne
1806 Saint-Léger (CH)
- VASLIN-CHESSEX, Anne
1008 Prilly (CH)
- WOJCIK, Jérôme
01220 Divonne-les-Bains (FR)
- ARMENISE, Claudia
01200 Eloise (FR)
|
| (74) |
Representative: KATZAROV S.A. |
|
European Patent Attorneys
12, Avenue des Morgines
1213 Petit-Lancy
1213 Petit-Lancy (CH) |
|
| |
|
|
|
Remarks: |
|
This application was filed on 07-05-2019 as a divisional application to the application
mentioned under INID code 62. |
|
|
|
Remarks: |
|
Claims filed after the date of filing of the application / after the date of receipt
of the divisional application (Rule 68(4) EPC). |
|
(57) The present invention relates to fusion polypeptides comprising an FGFR2 polypeptide
and to cDNAs encoding such fusion polypeptides. The invention also encompasses methods
of diagnosing the presence of the fusion polypeptides or of a gene or RNA sequence
coding therefore in a sample from a subject as well as methods of treatment of a tumor
instructed by the latter diagnosis.